Statins Safety Signals: From Precautions to Proportionate Evidence‐Based Labeling

The recent Cholesterol Treatment Trialists' Collaboration meta‐analysis provides the most comprehensive randomized evidence to date regarding statin‐associated adverse drug reactions, substantially narrowing the list of harms confidently attributable to statins. Beyond its clinical implications, the analysis highlights important challenges in pharmacovigilance and regulatory risk communication. Precautionary labeling based on low‐certainty evidence may inadvertently amplify nocebo effects, reduce adherence to preventive therapies, and contribute to avoidable cardiovascular burden, particularly among vulnerable populations.